Advertisement

Shire’s stalker raises its offer

US pharmaceuticals group AbbVie has made a fourth attempt to bag London-listed Shire Pharmaceuticals.

US pharmaceuticals group AbbVie has made a fourth attempt to bag London-listed Shire Pharmaceuticals. Its latest unsolicited bid is worth £30bn, or just over £51 a share an 11% improvement on the previous bid.

AbbVie urged Shire's shareholders to persuade the board to enter talks. AbbVie is best known for Humira, a rheumatoid arthritis drug. Shire specialises in drugs for attention deficit hyperactivity disorder.

What the commentators said

Back then, it was easy to point out that Pfizer was keen to take over Astra largely for tax purposes: it would keep its bills down by moving its domicile to the UK.

Advertisement - Article continues below

But this situation is different. While so-called tax inversion plays a part in AbbVie's motives, "Shire's role as a UK pharmaceutical powerhouse is undermined" by its own tax exile in Ireland, said Brummer; it has been based there for eight years. If AbbVie takes it over, Shire will actually come home.

In any case, Shire has never been a "research and development champion" in the Astra or GlaxoSmithKline mould.It has expanded largely by acquisition.

Plenty of shareholders will be happy with the offer, said Nils Pratley in The Guardian the shares traded at £35 before the bid surfaced. But AbbVie can pay more. Bank of America reckons it could stretch to £59 and still break even.

Shire's own growth target will also bolster its defences, said Navid Malik of Cenkos. It plans to double revenue by 2020, achievable given its "track record of building value". "Its value as a stand-alone company is very compelling."

Advertisement
Advertisement

Recommended

Visit/517688/the-british-equity-market-is-shrinking
Stockmarkets

The British equity market is shrinking

British startups are abandoning public stockmarkets and turning to deep-pocketed Silicon Valley venture capitalists for their investment needs.
8 Nov 2019
Visit/511212/reasons-for-investors-to-be-bearish-but-stick-with-the-stockmarket-bulls
Stockmarkets

There are lots of reasons to be bearish – but you should stick with the bulls

There are plenty of reasons to be gloomy about the stockmarkets. But the trend remains up, says Dominic Frisby. And you don’t want to bet against the …
17 Jul 2019
Visit/510684/good-news-on-jobs-scares-stockmarkets
Economy

Good news on jobs scares US stockmarkets

June brought the best monthly US jobs growth of the year, but stockmarkets were not best pleased.
11 Jul 2019
Visit/510135/trade-war-ceasefire-boosts-stockmarkets
Economy

Trade-war ceasefire boosts stockmarkets

Stockmarkets sighed with relief after the G20 summit in Japan brought a handshake between Donald Trump and Xi Jinping.
4 Jul 2019

Most Popular

Visit/investments/commodities/gold/601444/these-seven-charts-show-exactly-why-you-must-own-gold-today
Gold

These seven charts show exactly why you must own gold today

Covid-19 is accelerating many trends that were already in existence. The rising gold price is one such trend. These seven charts, says Dominic Frisby,…
3 Jun 2020
Visit/economy/eu-economy/601463/why-a-stronger-euro-is-good-news-for-investors
EU Economy

Why a stronger euro is good news for investors

The fragile state of the eurozone has for a long time brought the threat of deflation. But the ECB’s latest moves have dampened those fears. John Step…
5 Jun 2020
Visit/investments/stockmarkets/emerging-markets/601465/putins-grip-on-power-is-slipping
Emerging markets

Putin’s grip on power is slipping

The Russian president had been looking forward to a spring of triumphs, including a new constitution that strengthens his hand. Now he faces multiple …
6 Jun 2020